Abstract: An integrated coolant bottle assembly includes a reservoir configured for use in a thermal system. Examples of such thermal systems include a cooling/heating system of a battery powered electric vehicle, electric power generators (e.g., motor-based systems), other physical plant installations, etc. Such a reservoir includes a first section and a second section. The second section is joined to the first section at a reservoir interface thereby forming the reservoir that is configured for storage and/or flow of a liquid medium. The first section may include an integrated channel that provides a pathway for the flow of the liquid medium. The reservoir may also include a component interface configured to facilitate connection of a component thereto (e.g., a pump, a battery pump, a powertrain pump, a chiller, a heater, a filter, an aerator, a valve, a connector, a fan, or a radiator).

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: An integrated coolant bottle assembly includes a reservoir configured for use in a thermal system. Examples of such thermal systems include a cooling/heating system of a battery powered electric vehicle, electric power generators (e.g., motor-based systems), other physical plant installations, etc. Such a reservoir includes a first section and a second section. The second section is joined to the first section at a reservoir interface thereby forming the reservoir that is configured for storage and/or flow of a liquid medium. The first section may include an integrated channel that provides a pathway for the flow of the liquid medium. The reservoir may also include a component interface configured to facilitate connection of a component thereto (e.g., a pump, a battery pump, a powertrain pump, a chiller, a heater, a filter, an aerator, a valve, a connector, a fan, or a radiator).

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X5, X7, R1, and Q1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.

Abstract: Compounds of formula (II) have antibacterial activity: wherein: Q represents a radical of formula —N(OH)CH(?0) or formula —C(?O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl or, except when Q is a radical of formula —N(OH)CH(?0), a hydroxy, halo or amino group; R2 represents a group R10—(D)n—(ALK)m— wherein R10 represents hydrogen or an optionally substituted C-C6 alkyl, C2-C6 alkynyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group and ALK represents a straight or branched divalent C-C6 alkylene, C2-C6 alkynylene, or C2-C6 alkynylene radical, and may be interrupted by one or more non-adjacent —NH—, —O—or -Slinkages, D represents —NH—, —O—or —S—, and m and n are independently 0 or 1; R4 represents the side chain of a natural or non-natural alpha amino acid; ring A represents an optionally substituted monocyclic heterocyclic ring containing from 5 to 7 ring atoms, one of which is the nitrogen atom shown, the remaining ring atoms being selected from compatible combinations of carbon, oxygen,

Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

Abstract: Process for temperature-dependent actuation of a supplemental pressure medium source in slippage-controlled motor vehicle braking systems. The invention pertains to a process for operating a slippage-controlled motor vehicle braking system with regulation of driving dynamics. In such systems it has thus far been proposed to turn on supplemental pressure medium sources to support the supply pump when regulation starts, in order to shorten the regulation time. Practical studies have shown that such supplemental sources are, first of all, not needed for each regulation process and, second, cause disruptive noise. The invention thus proposes to turn on the supplemental pressure medium source only in the presence of special situations, such as if the pressure medium is very viscous due to low temperatures. Advantageous refinements are concerned with determination of the temperature.